JP2023532217A - Ｓｈｐ２阻害剤の結晶形、その組成物、その製造方法及び応用 - Google Patents

Ｓｈｐ２阻害剤の結晶形、その組成物、その製造方法及び応用 Download PDF

Info

Publication number
JP2023532217A
JP2023532217A JP2022577746A JP2022577746A JP2023532217A JP 2023532217 A JP2023532217 A JP 2023532217A JP 2022577746 A JP2022577746 A JP 2022577746A JP 2022577746 A JP2022577746 A JP 2022577746A JP 2023532217 A JP2023532217 A JP 2023532217A
Authority
JP
Japan
Prior art keywords
crystalline form
theta
degrees
spectrum
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022577746A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532217A5 (cg-RX-API-DMAC7.html
Inventor
乾 剛 鄭
葛 浩 諸
▲イエ▼ 趙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Etern BioPharma Shanghai Co Ltd
Original Assignee
Etern BioPharma Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Etern BioPharma Shanghai Co Ltd filed Critical Etern BioPharma Shanghai Co Ltd
Publication of JP2023532217A publication Critical patent/JP2023532217A/ja
Publication of JP2023532217A5 publication Critical patent/JP2023532217A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022577746A 2020-06-18 2021-06-17 Ｓｈｐ２阻害剤の結晶形、その組成物、その製造方法及び応用 Pending JP2023532217A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020096778 2020-06-18
CNPCT/CN2020/096778 2020-06-18
PCT/CN2021/100673 WO2021254449A1 (zh) 2020-06-18 2021-06-17 一种shp2抑制剂的晶型及其组合物、制备方法和用途

Publications (2)

Publication Number Publication Date
JP2023532217A true JP2023532217A (ja) 2023-07-27
JP2023532217A5 JP2023532217A5 (cg-RX-API-DMAC7.html) 2024-06-25

Family

ID=79268476

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022577746A Pending JP2023532217A (ja) 2020-06-18 2021-06-17 Ｓｈｐ２阻害剤の結晶形、その組成物、その製造方法及び応用

Country Status (8)

Country Link
US (1) US20230339975A1 (cg-RX-API-DMAC7.html)
EP (1) EP4169920A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023532217A (cg-RX-API-DMAC7.html)
KR (1) KR20230026458A (cg-RX-API-DMAC7.html)
CN (1) CN115698007A (cg-RX-API-DMAC7.html)
AU (1) AU2021290733A1 (cg-RX-API-DMAC7.html)
CA (1) CA3183063A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021254449A1 (cg-RX-API-DMAC7.html)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020094018A1 (zh) * 2018-11-06 2020-05-14 上海奕拓医药科技有限责任公司 一种螺芳环化合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3860717A1 (en) * 2018-10-03 2021-08-11 Gilead Sciences, Inc. Imidozopyrimidine derivatives
JP2022506887A (ja) * 2018-11-07 2022-01-17 シャンハイ リンジーン バイオファーマ カンパニー リミテッド 窒素含有縮合複素環系ｓｈｐ２阻害剤化合物、製造方法及び使用
EP3889153A4 (en) * 2018-11-30 2022-09-07 Tuojie Biotech (Shanghai) Co., Ltd. PYRIMIDINE AND FIVE-MEMBERED HETEROCYCLIC NITROGEN DERIVATIVE, METHOD OF MANUFACTURE THEREOF AND MEDICAL USES THEREOF
US20220073521A1 (en) * 2018-11-30 2022-03-10 Tuojie Biotech (Shanghai) Co., Ltd. Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof
KR20220054285A (ko) * 2019-06-28 2022-05-02 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 피리미딘 5 원 질소 헤테로고리형 유도체, 이의 제조 방법 및 이의 약학적 용도
WO2021088945A1 (zh) * 2019-11-08 2021-05-14 南京圣和药业股份有限公司 作为shp2抑制剂的化合物及其应用
CN113754683A (zh) * 2020-06-05 2021-12-07 上海奕拓医药科技有限责任公司 同位素取代的螺芳环化合物及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020094018A1 (zh) * 2018-11-06 2020-05-14 上海奕拓医药科技有限责任公司 一种螺芳环化合物及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
平山令明編, 有機化合物結晶作製ハンドブック −原理とノウハウ−, JPN6011053065, 25 July 2008 (2008-07-25), pages 57 - 84, ISSN: 0005636829 *
芦澤一英, 医薬品の多形現象と晶析の科学, JPN6018028449, 2002, pages 56 - 102, ISSN: 0005636830 *

Also Published As

Publication number Publication date
KR20230026458A (ko) 2023-02-24
EP4169920A1 (en) 2023-04-26
CN115698007A (zh) 2023-02-03
WO2021254449A1 (zh) 2021-12-23
US20230339975A1 (en) 2023-10-26
CA3183063A1 (en) 2021-12-23
AU2021290733A1 (en) 2023-02-23
EP4169920A4 (en) 2024-08-07

Similar Documents

Publication Publication Date Title
AU2016253550B2 (en) A crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2- carboxamide hydrochloride monohydrate
WO2017152707A1 (zh) 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用
TWI796250B (zh) 經取代之 5,6-二氫-6-苯基苯并[f]異喹啉-2-胺化合物之固體形式
KR102847760B1 (ko) 디아미노피리미딘 화합물 또는 이의 수화물의 고체 형태, 이의 제조 방법 및 이의 용도
JP2023532217A (ja) Ｓｈｐ２阻害剤の結晶形、その組成物、その製造方法及び応用
EP3941472B1 (en) Crystalline and amorphous forms of-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2 <ns1:i>h</ns1:i>?-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof
EP4631937A1 (en) Crystalline form or amorphous form of oxoisoindole-5-formamide compound or salt and solvate thereof
WO2019234435A1 (en) Salt form
RU2792620C2 (ru) Кристаллическая форма ингибитора parp-1 и способ ее получения
CN102341392A (zh) 二氢苯并噁唑-6-基-乙酰胺衍生物的新的结晶水合物、无定形和多晶型形式及其制备方法
WO2024214044A1 (en) Multicomponent complexes, including salts and hydrates and solvates, of inupadenant
HK40079038A (en) Method of preparing solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
TW201904972A (zh) 一種咪唑并異吲哚類衍生物游離鹼的晶型及其製備方法
HK1225719A1 (en) Pharmaceutical formulations comprising crystalline forms of (r)-7-chloro-n-(quinuclidin-3-yl) benzo(b)thiophene-2-carboxamide hydrochloride monohydrate
HK1234747B (zh) 取代的咪唑并吡啶基-氨基吡啶化合物的盐和多晶型
HK1183034B (en) A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240617

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250411

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250708